BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -236.3 Million SEK | 51.59% |
| 2022 | -488.08 Million SEK | 44.69% |
| 2021 | -882.38 Million SEK | -22.95% |
| 2020 | -717.66 Million SEK | -418.37% |
| 2019 | -138.44 Million SEK | -101.08% |
| 2018 | -68.85 Million SEK | 33.61% |
| 2017 | -103.7 Million SEK | 54.14% |
| 2016 | -226.11 Million SEK | -465.67% |
| 2015 | -39.97 Million SEK | 12.39% |
| 2014 | -45.62 Million SEK | 29.53% |
| 2013 | -64.74 Million SEK | 35.29% |
| 2012 | -100.06 Million SEK | -8.36% |
| 2011 | -92.34 Million SEK | -149.9% |
| 2010 | -36.95 Million SEK | 50.09% |
| 2009 | -74.03 Million SEK | -351.6% |
| 2008 | -16.39 Million SEK | 36.06% |
| 2007 | -25.63 Million SEK | 62.33% |
| 2006 | -68.05 Million SEK | 49.79% |
| 2005 | -135.53 Million SEK | 22.29% |
| 2004 | -174.4 Million SEK | 35.04% |
| 2003 | -268.47 Million SEK | 21.86% |
| 2002 | -343.58 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -451.14 Million SEK | -0.71% |
| 2024 Q1 | -447.95 Million SEK | -89.57% |
| 2024 Q3 | -708.65 Million SEK | -55.24% |
| 2023 Q4 | -236.3 Million SEK | 58.44% |
| 2023 Q3 | -568.59 Million SEK | -3.87% |
| 2023 FY | -236.3 Million SEK | 51.59% |
| 2023 Q2 | -547.43 Million SEK | -5.79% |
| 2023 Q1 | -517.46 Million SEK | -6.02% |
| 2022 Q1 | -743.01 Million SEK | 15.8% |
| 2022 Q3 | -672.73 Million SEK | -18.85% |
| 2022 Q4 | -488.08 Million SEK | 27.45% |
| 2022 FY | -488.08 Million SEK | 44.69% |
| 2022 Q2 | -566.03 Million SEK | 23.82% |
| 2021 Q4 | -882.38 Million SEK | 28.06% |
| 2021 FY | -882.38 Million SEK | -22.95% |
| 2021 Q1 | -1.56 Billion SEK | -118.33% |
| 2021 Q3 | -1.22 Billion SEK | 17.03% |
| 2021 Q2 | -1.47 Billion SEK | 5.65% |
| 2020 Q1 | -103.04 Million SEK | 25.57% |
| 2020 FY | -717.66 Million SEK | -418.37% |
| 2020 Q4 | -717.66 Million SEK | -13.75% |
| 2020 Q3 | -630.92 Million SEK | -271.9% |
| 2020 Q2 | -169.64 Million SEK | -64.64% |
| 2019 Q3 | -166.93 Million SEK | 13.03% |
| 2019 Q4 | -138.44 Million SEK | 17.07% |
| 2019 FY | -138.44 Million SEK | -101.08% |
| 2019 Q1 | -8.65 Million SEK | 87.43% |
| 2019 Q2 | -191.95 Million SEK | -2117.12% |
| 2018 Q1 | -78.05 Million SEK | 24.73% |
| 2018 FY | -68.85 Million SEK | 33.61% |
| 2018 Q2 | -144.7 Million SEK | -85.39% |
| 2018 Q4 | -68.85 Million SEK | 35.71% |
| 2018 Q3 | -107.09 Million SEK | 25.99% |
| 2017 Q4 | -103.7 Million SEK | 36.2% |
| 2017 FY | -103.7 Million SEK | 54.14% |
| 2017 Q1 | -216.03 Million SEK | 4.46% |
| 2017 Q2 | -192.77 Million SEK | 10.77% |
| 2017 Q3 | -162.55 Million SEK | 15.68% |
| 2016 FY | -226.11 Million SEK | -465.67% |
| 2016 Q3 | -196.41 Million SEK | 12.49% |
| 2016 Q2 | -224.45 Million SEK | -441.62% |
| 2016 Q1 | -41.44 Million SEK | -3.67% |
| 2016 Q4 | -226.11 Million SEK | -15.12% |
| 2015 Q1 | -25.74 Million SEK | 43.57% |
| 2015 Q4 | -39.97 Million SEK | 20.9% |
| 2015 Q3 | -50.53 Million SEK | 19.41% |
| 2015 Q2 | -62.7 Million SEK | -143.55% |
| 2015 FY | -39.97 Million SEK | 12.39% |
| 2014 Q4 | -45.62 Million SEK | 35.18% |
| 2014 FY | -45.62 Million SEK | 29.53% |
| 2014 Q3 | -70.39 Million SEK | 5.25% |
| 2014 Q2 | -74.29 Million SEK | -77.85% |
| 2014 Q1 | -41.77 Million SEK | 35.48% |
| 2013 FY | -64.74 Million SEK | 35.29% |
| 2013 Q2 | -39.76 Million SEK | 48.44% |
| 2013 Q3 | -39.94 Million SEK | -0.45% |
| 2013 Q1 | -77.12 Million SEK | 22.92% |
| 2013 Q4 | -64.74 Million SEK | -62.1% |
| 2012 FY | -100.06 Million SEK | -8.36% |
| 2012 Q1 | -101.55 Million SEK | -9.98% |
| 2012 Q2 | -93.69 Million SEK | 7.74% |
| 2012 Q3 | -96.62 Million SEK | -3.12% |
| 2012 Q4 | -100.06 Million SEK | -3.56% |
| 2011 Q1 | -27.77 Million SEK | 24.82% |
| 2011 Q2 | -15.53 Million SEK | 44.08% |
| 2011 Q3 | -18.95 Million SEK | -22.02% |
| 2011 Q4 | -92.34 Million SEK | -387.22% |
| 2011 FY | -92.34 Million SEK | -149.9% |
| 2010 Q1 | -29.31 Million SEK | 60.41% |
| 2010 FY | -36.95 Million SEK | 50.09% |
| 2010 Q3 | -33.05 Million SEK | -67.18% |
| 2010 Q2 | -19.77 Million SEK | 32.53% |
| 2010 Q4 | -36.95 Million SEK | -11.78% |
| 2009 Q4 | -74.03 Million SEK | 0.0% |
| 2009 FY | -74.03 Million SEK | -351.6% |
| 2008 FY | -16.39 Million SEK | 36.06% |
| 2007 FY | -25.63 Million SEK | 62.33% |
| 2006 FY | -68.05 Million SEK | 49.79% |
| 2005 FY | -135.53 Million SEK | 22.29% |
| 2004 FY | -174.4 Million SEK | 35.04% |
| 2003 FY | -268.47 Million SEK | 21.86% |
| 2002 FY | -343.58 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -372.41% |
| Ziccum AB (publ) | -2.13 Million SEK | -10957.745% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -1139.79% |
| BioArctic AB (publ) | -606.58 Million SEK | 61.044% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -373.233% |
| Mendus AB (publ) | -96.29 Million SEK | -145.398% |
| Genovis AB (publ.) | -43.94 Million SEK | -437.776% |
| Intervacc AB (publ) | -88.16 Million SEK | -168.04% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 1252.14% |
| Active Biotech AB (publ) | -33.2 Million SEK | -611.759% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 543.989% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -500.03% |
| Aptahem AB (publ) | 2.9 Million SEK | 8224.204% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 29.17% |
| Kancera AB (publ) | -45.69 Million SEK | -417.167% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 28.189% |
| Fluicell AB (publ) | -2.76 Million SEK | -8452.443% |
| Saniona AB (publ) | 40.44 Million SEK | 684.231% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -640.138% |
| Biovica International AB (publ) | -58.73 Million SEK | -302.309% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -422.6% |
| AcouSort AB (publ) | -23.98 Million SEK | -885.175% |
| Xintela AB (publ) | -7.8 Million SEK | -2926.047% |
| Abliva AB (publ) | -57.24 Million SEK | -312.83% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | -21.368% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -187.467% |
| OncoZenge AB (publ) | -12.62 Million SEK | -1771.418% |
| Amniotics AB (publ) | -5.63 Million SEK | -4095.739% |
| 2cureX AB (publ) | -13.4 Million SEK | -1663.068% |
| CombiGene AB (publ) | -101.44 Million SEK | -132.95% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -10834.938% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 4476.0% |
| Camurus AB (publ) | -1.16 Billion SEK | 79.722% |
| Corline Biomedical AB | -17.01 Million SEK | -1289.043% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -182.178% |
| Isofol Medical AB (publ) | -138.14 Million SEK | -71.051% |
| I-Tech AB | -83.26 Million SEK | -183.808% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 275.419% |
| Cyxone AB (publ) | -16.67 Million SEK | -1317.54% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -322.832% |
| Biosergen AB | -1.88 Million SEK | -12449.336% |
| Cantargia AB (publ) | -139.74 Million SEK | -69.094% |
| NextCell Pharma AB | -46.79 Million SEK | -405.024% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | -82.481% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -704.221% |
| Nanologica AB (publ) | -9.38 Million SEK | -2417.086% |
| SynAct Pharma AB | -61.75 Million SEK | -282.629% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -1003.451% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -1686.233% |
| LIDDS AB (publ) | -13.51 Million SEK | -1648.845% |
| Lipum AB (publ) | -8.46 Million SEK | -2691.542% |
| Alzinova AB (publ) | -21.22 Million SEK | -1013.276% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -253.114% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -4461.043% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -182.184% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -25501.733% |
| Simris Alg AB (publ) | 85.07 Million SEK | 377.76% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -187.874% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 242.286% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -1036.459% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -7851.009% |